TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Cytokinetics, Incorporated
Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update

Cytokinetics reported strong progress towards potential FDA approval of aficamten for hypertrophic cardiomyopathy by December 26, 2025, with ongoing regulatory reviews in the U.S., China, and E.U. The company maintains a strong cash position of $1.25 billion and continues advancing multiple cardiac muscle treatment programs.

Insights
CYTK   positive

Strong financial position, advancing multiple clinical programs, progressing towards potential FDA approval of aficamten, expanding commercial readiness, and demonstrating strategic execution in cardiac muscle treatment development